AR052266A1 - Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos - Google Patents

Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos

Info

Publication number
AR052266A1
AR052266A1 ARP050105197A ARP050105197A AR052266A1 AR 052266 A1 AR052266 A1 AR 052266A1 AR P050105197 A ARP050105197 A AR P050105197A AR P050105197 A ARP050105197 A AR P050105197A AR 052266 A1 AR052266 A1 AR 052266A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
group
atoms
membered heterocyclic
Prior art date
Application number
ARP050105197A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34090028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR052266A1 publication Critical patent/AR052266A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)

Abstract

Un proceso para prepararlos, y su uso como productos farmacéuticos. Reivindicacion 1: Un compuesto de la formula (1) en forma libre o de sal farmacéuticamente aceptable, en donde Q es [cR1R2]m; R1 y R2 son independientemente H, alquilo C1-8, o junto con el átomo de C con el que están unidos, forman un grupo cicloalifático divalente de 3 a 8 átomos de C; R3 y R4 se seleccionan independientemente a partir de H y alquilo C1-8; R5 se selecciona a partir de H, halogeno, alquilo C1-8, haloalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, nitro, ciano, SO2R5a, SOR5b, SR5c, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, alcoxilo C1-8, haloalcoxilo C1-8, carboxilo, carboxi-alquilo C1-8, amino, amino-(alquilo C1-8), alquilo C1-8-amino, di-(alquilo C1-8)-amino, SO2NR5dR5e, -C(O)NR5fR5g, un grupo carbocíclico aromático de 6 a 15 átomos de C, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; R5a, R5b y R5c se seleccionan independientemente a partir de alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)- amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S; R5d, R5e, R5f, y R5g son independientemente H, alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8- amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S; o junto con el átomo de N con el que están unidos, forman un grupo heterocíclico de 4 a 10 átomos de C; R6 se selecciona a partir de H, halogeno, alquilo C1-8, haloalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, nitro, ciano, SO2R6a, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, alcoxilo C1-8, haloalcoxilo C1-8, -SR6b, carboxilo, carboxi-alquilo C1-8, amino, amino-(alquilo C1-8), alquilo C18-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1- 8), alquilo C1-8-amino, di-(alquilo C1-8)-amino, SO2NR6cR6d, -C(O)NR6eR6f, hidroxialquilo C1-8, NR6gSO2R6h, NR6i(CO)R6j, SOR6k, un grupo carbocíclico aromático de 6 a 15 átomos de C, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; R6a, R6k, y R6b se seleccionan independientemente a partir de alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; R6c, R6d,R6e, y R6f son independientemente H, alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S, o junto con el átomo de N con el que están unidos, forman un grupo heterocíclico de 4 a 10 átomos de C; R6g y R6i se seleccionan independientemente a partir de H, alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S; R6h y R6j se seleccionan independientemente a partir de alquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S, hidroxialquilo C1-8, amino-(alquilo C1-8), alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), y cianoalquilo C1-8;W se selecciona a partir de un grupo carbocíclico de 3 a 15 átomos de C, y un heterociclo de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; m es un entero seleccionado a partir de 1 a 3; y n es un entero seleccionado a partir de 1 a 4.
ARP050105197A 2004-12-14 2005-12-12 Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos AR052266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0427381.9A GB0427381D0 (en) 2004-12-14 2004-12-14 Organic compounds

Publications (1)

Publication Number Publication Date
AR052266A1 true AR052266A1 (es) 2007-03-07

Family

ID=34090028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105197A AR052266A1 (es) 2004-12-14 2005-12-12 Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos

Country Status (21)

Country Link
US (1) US20100087432A1 (es)
EP (1) EP1828172B1 (es)
JP (1) JP2008523130A (es)
KR (1) KR20070087605A (es)
CN (1) CN101072773B (es)
AR (1) AR052266A1 (es)
AT (1) ATE449772T1 (es)
AU (1) AU2005315881C1 (es)
BR (1) BRPI0518607A2 (es)
CA (1) CA2587934A1 (es)
DE (1) DE602005017935D1 (es)
ES (1) ES2335519T3 (es)
GB (1) GB0427381D0 (es)
GT (1) GT200500360A (es)
MX (1) MX2007007098A (es)
PE (1) PE20060736A1 (es)
PL (1) PL1828172T3 (es)
PT (1) PT1828172E (es)
RU (1) RU2007126761A (es)
TW (1) TW200635921A (es)
WO (1) WO2006063763A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
EP2229358B1 (en) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
EP2401269B1 (en) * 2009-02-24 2014-01-29 Merck Sharp & Dohme Corp. Indole derivatives as crth2 receptor antagonists
EP2516416A1 (en) 2009-12-23 2012-10-31 Ironwood Pharmaceuticals, Inc. Crth2 modulators
MA34094B1 (fr) 2010-03-22 2013-03-05 Actelion Pharmaceuticals Ltd Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
WO2011117184A1 (de) 2010-03-24 2011-09-29 Bayer Cropscience Ag Fludioxonil-derivate
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20140187795A1 (en) * 2010-12-08 2014-07-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators and preparation thereof
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
US20150080381A1 (en) * 2012-04-12 2015-03-19 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
ES2461415B1 (es) * 2012-10-16 2015-03-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados funcionalizados e inmunorreactivos para el fungicida fludioxonil
CN103553990B (zh) * 2013-11-08 2016-01-20 苏州诚和医药化学有限公司 用卤素卤化合成2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法
CN103588686B (zh) * 2013-11-08 2016-01-20 苏州诚和医药化学有限公司 一种用卤素卤化制备2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法
CN103553991B (zh) * 2013-11-08 2016-01-20 苏州诚和医药化学有限公司 一种制备2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
CN108164502B (zh) * 2018-03-06 2021-04-13 苏州华一新能源科技有限公司 1,3-丙烷磺酸内酯的制备方法
CN112602714B (zh) * 2020-12-23 2021-11-16 华南农业大学 一类咯菌腈羧酸衍生物在用于植物维管组织靶向药剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182737A3 (de) * 1984-10-16 1986-10-08 Ciba-Geigy Ag 3-Phenylpyrrolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
EP0386681A1 (de) * 1989-03-08 1990-09-12 Ciba-Geigy Ag 3-Aryl-4-cyano-pyrrol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende mikrobiozide Mittel
JP4316232B2 (ja) * 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
CA2471754A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Androgen receptor antagonist
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EA200602288A1 (ru) * 2004-05-29 2007-10-26 7ТиЭм ФАРМА А/С Замещённые тиазолуксусные кислоты в качестве лигандов crth2

Also Published As

Publication number Publication date
AU2005315881A1 (en) 2006-06-22
CN101072773A (zh) 2007-11-14
GT200500360A (es) 2006-08-07
ES2335519T3 (es) 2010-03-29
US20100087432A1 (en) 2010-04-08
EP1828172A1 (en) 2007-09-05
PL1828172T3 (pl) 2010-05-31
ATE449772T1 (de) 2009-12-15
BRPI0518607A2 (pt) 2008-11-25
MX2007007098A (es) 2007-06-22
AU2005315881C1 (en) 2010-03-11
AU2005315881B2 (en) 2009-09-24
CA2587934A1 (en) 2006-06-22
TW200635921A (en) 2006-10-16
CN101072773B (zh) 2011-01-19
KR20070087605A (ko) 2007-08-28
PE20060736A1 (es) 2006-09-08
PT1828172E (pt) 2010-02-17
GB0427381D0 (en) 2005-01-19
EP1828172B1 (en) 2009-11-25
DE602005017935D1 (de) 2010-01-07
WO2006063763A1 (en) 2006-06-22
RU2007126761A (ru) 2009-01-27
JP2008523130A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
AR052266A1 (es) Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
LTPA2016032I1 (lt) Hipoglikeminių agentų skyrimo būdai
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
SV2010003767A (es) Compuestos pirazolicos 436
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos
BRPI0606112B8 (pt) 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos
ATE539079T1 (de) Imidazochinoxalinverbindungen als immunmodulatoren
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
AR082844A1 (es) Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos
AR083268A1 (es) Conjugado de naloxol-peg cristalino
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
AR054000A1 (es) Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
DOP2011000335A (es) Combinacion antitumoral que comprende ave8062 y sorafenib
AR063027A1 (es) Derivados de sulfonamida
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
ITFI20070287A1 (it) "un complesso espositore per la presentazione al pubblico di prodotti confezionati, con attivatori ottici e/o acustici"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal